ERBB2 and gastroesophageal junction adenocarcinoma: The updated result on OS benefit was reported in ESMO 2024.38 In this randomized, double-blind trial, a total of 698 patients with histologically confirmed HER-2 positive metastatic G/GEJ adenocarcinoma were randomized in 1:1 to trastuzumab + standard of care chemotherapy with or without pembrolizumab.